80,000 UK Biobank Samples to Be Tested for Pre-Symptom Brain Proteins

By Amara Osei

An 80,000-sample UK Biobank study will test whether Alamar Biosciences' ultrasensitive NULISA platform can detect blood proteins linked to neurodegeneration that conventional assays barely register. The Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Research UK and LifeArc are funding the project, announced November 2, with completion expected by the end of 2027.

The premise rests on a measurable technical gap. Many candidate protein markers of Alzheimer's and Parkinson's disease circulate at concentrations too low for standard immunoassays to quantify reliably. NULISA — NUcleic acid Linked Immuno-Sandwich Assay — attaches DNA oligonucleotide tags to antibodies that capture a target protein, then uses a capture-and-release step to wash away background signal before reading the DNA reporters by next-generation sequencing. Whether that sensitivity translates into usable signal across 80,000 real-world samples remains the open question.

Who runs what?

Nightingale Health will run the measurements in its own laboratories, quantifying hundreds of circulating proteins from UK Biobank participants under the study's full name: UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife, or UKB-PRISM. The scale is substantial — 80,000 samples processed within roughly a 14-month window ending in 2027.

The sponsor mix matters for interpretation. Two of the three funders are disease-focused charities with therapeutic portfolios; LifeArc is a medical research charity that commercializes early-stage science. None is a disinterested academic funder, so claims about diagnostic potential warrant scrutiny once data appear.

What do the backers claim?

The study's timing reflects a growing consensus that Alzheimer's and Parkinson's biology begins years before diagnosis. The companies cited the scale of the problem: dementias including Alzheimer's affect more than 55 million people worldwide, Parkinson's more than 12 million, and both figures are projected to rise sharply by 2050.

Yuling Luo, PhD, Alamar's founder, CEO and chair, framed the ambition directly. "Working with Nightingale and UK Biobank, we can now measure those signals across tens of thousands of people, years before symptoms appear, and give researchers everywhere a new way to ask when and why these diseases begin," she said.

UK Biobank's deputy chief scientist, Adam Lewandowski, PhD, was more restrained about the state of knowledge. Proteins repair tissue and regulate inflammation, he noted, "yet we still know relatively little about how they work together to influence brain health."

Samantha Hutten, PhD, principal biomarker scientist in translational research at the Michael J. Fox Foundation, said the dataset could help "evaluate potential biomarkers and inform future therapeutic research." LifeArc CEO Sam Barrell pointed to rare dementias, whose overlapping symptoms make diagnosis difficult, saying the resource could lay "the groundwork for more accurate diagnosis." Both statements are projections, not measured outcomes; no sensitivity or specificity figures have been published for NULISA on neurodegeneration markers at this cohort scale.

What happens to the data?

Once the study concludes, the full dataset will be available to approved researchers worldwide through the UK Biobank Research Analysis Platform. That access model gives the work value beyond the two companies' commercial interests, though the platform's approval process and any embargo periods before release were not specified in the announcement.

For R&D managers, the near-term relevance is limited to assay selection and partnership evaluation rather than immediate clinical decisions. The study measures; it does not validate a diagnostic. Whether the 2027 dataset yields reproducible pre-symptom signatures — and whether those signatures survive independent replication across populations outside the UK Biobank's cohort — will determine if this becomes a screening tool or another biomarker archive.